News

A new artificial intelligence (AI)-based model that combines information from imaging scans and blood levels of a protein called matrix metalloproteinase-7 (MMP-7) may aid in…

A late-stage clinical trial assessing the safety and effectiveness of Mirum Pharmaceuticals’ brelovitug for adults with chronic hepatitis D has completed enrollment, and…

Hispanic people with primary biliary cholangitis (PBC) are significantly less likely to achieve complete lab-based remission — defined as a normalization of the liver damage…

Long-term exposure to particles produced from cooking grilled meat can trigger liver damage and cholestasis — slowing or stalling of the digestive fluid bile…

The first participant has been dosed in a large clinical trial testing TGM-312, a novel gene-silencing therapy designed to slow the progression of metabolic dysfunction-associated…

Children with Alagille syndrome who have lower blood levels of bile acids, the main component of the digestive fluid bile, have better long-term liver…

In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…

Use of the experimental immune-modulating therapy CNP-104 in adults with primary biliary cholangitis (PBC) participating in a U.S. clinical trial led to greater reductions in markers…

Among children and adolescents with progressive familial intrahepatic cholestasis (PFIC), severe itch significantly affects sleep, overall perceptions of health, and the family’s quality of…

People whose biological parents were overweight or obese at the time of their conception face a greater risk of early liver disease, according to a…